Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELZ NASDAQ:ELAB NASDAQ:OBSV NASDAQ:SYBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELZCreative Medical Technology$2.06-2.8%$2.21$1.50▼$6.25$7.62M1.8450,848 shs65,056 shsELABPMGC$1.54-8.9%$3.02$1.50▼$309.12$1.79M-0.271.40 million shs740,572 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs13,679 shsSYBXSynlogic$0.69-1.4%$0.64$0.54▼$1.96$8.19M0.5664,165 shs6,170 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELZCreative Medical Technology-3.74%-8.44%-7.62%+9.57%-9.25%ELABPMGC-8.88%-12.99%-27.70%-65.30%-99.17%OBSVObsEva0.00%0.00%0.00%+400.00%-50.00%SYBXSynlogic-1.43%+1.47%+15.00%+16.95%-43.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELZCreative Medical Technology$2.06-2.8%$2.21$1.50▼$6.25$7.62M1.8450,848 shs65,056 shsELABPMGC$1.54-8.9%$3.02$1.50▼$309.12$1.79M-0.271.40 million shs740,572 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs13,679 shsSYBXSynlogic$0.69-1.4%$0.64$0.54▼$1.96$8.19M0.5664,165 shs6,170 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELZCreative Medical Technology-3.74%-8.44%-7.62%+9.57%-9.25%ELABPMGC-8.88%-12.99%-27.70%-65.30%-99.17%OBSVObsEva0.00%0.00%0.00%+400.00%-50.00%SYBXSynlogic-1.43%+1.47%+15.00%+16.95%-43.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELZCreative Medical Technology 1.50ReduceN/AN/AELABPMGC 1.00SellN/AN/AOBSVObsEva 0.00N/AN/AN/ASYBXSynlogic 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ELAB, SYBX, CELZ, and OBSV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026CELZCreative Medical Technology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELZCreative Medical Technology$10K762.20N/AN/A$2.04 per share1.01ELABPMGC$1.27M1.40N/AN/A$93.33 per share0.02OBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ASYBXSynlogic$8K1,008.87N/AN/A$1.09 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELZCreative Medical Technology-$5.99M-$2.14N/AN/AN/AN/A-88.38%-84.71%8/14/2026 (Estimated)ELABPMGC-$7.75M-$168.62N/AN/AN/AN/A-117.82%-70.79%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ASYBXSynlogic-$23.36M-$0.06N/AN/AN/AN/A-26.47%-18.00%N/ALatest ELAB, SYBX, CELZ, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ELABPMGCN/A-$11.2190N/A-$11.2190N/A$0.68 million5/8/2026Q1 2026CELZCreative Medical Technology-$0.39-$0.38+$0.01-$0.38$0.00 millionN/A3/30/2026Q4 2025ELABPMGCN/A-$52.7570N/A-$52.7570N/A$0.30 million3/20/2026Q4 2025CELZCreative Medical Technology-$0.37-$0.80-$0.43-$0.80N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELZCreative Medical TechnologyN/AN/AN/AN/AN/AELABPMGCN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ASYBXSynlogicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELZCreative Medical TechnologyN/A19.6719.67ELABPMGC0.031.451.43OBSVObsEvaN/A0.610.61SYBXSynlogicN/A2.652.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELZCreative Medical Technology1.42%ELABPMGC22.22%OBSVObsEva17.52%SYBXSynlogic63.40%Insider OwnershipCompanyInsider OwnershipCELZCreative Medical Technology1.70%ELABPMGC0.01%OBSVObsEva14.40%SYBXSynlogic2.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELZCreative Medical Technology53.70 million3.63 millionNot OptionableELABPMGC181.16 million1.16 millionN/AOBSVObsEva5077.97 million66.74 millionNot OptionableSYBXSynlogic8011.70 million11.39 millionNo DataELAB, SYBX, CELZ, and OBSV HeadlinesRecent News About These CompaniesSynlogic (NASDAQ:SYBX) Stock Crosses Below 50 Day Moving Average - Time to Sell?May 29, 2026 | americanbankingnews.comSynlogic's Strategic Crossroads: A Company in LimboFebruary 10, 2026 | aktiencheck.deASynlogic Challenges Nasdaq Delisting NoticeNovember 26, 2025 | tipranks.comWe Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business GrowthSeptember 18, 2025 | uk.finance.yahoo.comSynlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo FinanceJune 28, 2025 | finance.yahoo.comSynlogic's executive sells shares worth $2,802February 5, 2025 | msn.comSynlogic Reports Q3 2024 Financial OutcomesNovember 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSynlogic Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comSynlogic preps phenylketonuria drug for phase 3 after mid-stage winNovember 6, 2024 | pharmaphorum.comPSynlogic, Inc. (0A8U.L)August 24, 2024 | nz.finance.yahoo.comMIN.SG,0P0001I7V6,0 (MIN.SG)August 16, 2024 | nz.finance.yahoo.comMaintaining Hold on Synlogic Amid Strategic Reassessment and Financial UncertaintyAugust 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deSYBX Stock Earnings: Synlogic Beats EPS for Q2 2024August 8, 2024 | investorplace.comSynlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comSynlogic Inc.July 21, 2024 | wsj.comSynlogic Inc SYBXJuly 21, 2024 | morningstar.comMThe Summer Stock Exodus: 3 Companies to Ditch Before the Heat HitsMay 23, 2024 | investorplace.comHold Rating Maintained for Synlogic Amidst Setbacks and Financial UncertaintiesMay 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELAB, SYBX, CELZ, and OBSV Company DescriptionsCreative Medical Technology NASDAQ:CELZ$2.06 -0.06 (-2.83%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$2.10 +0.04 (+1.94%) As of 06/5/2026 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.PMGC NASDAQ:ELAB$1.54 -0.15 (-8.88%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.55 +0.01 (+0.84%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Synlogic NASDAQ:SYBX$0.69 -0.01 (-1.43%) As of 06/5/2026 02:19 PM EasternSynlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
